Anti-Mullerian hormone as an ovarian reserve marker in women
with the most frequent muscular dystrophies

J 2020

Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies

PARMOVÁ, Olesja; Eva VLČKOVÁ; Monika HULOVÁ; Livie MENSOVA; Igor CRHA et. al.

Základní údaje

Originální název

Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies

Autoři

Vydání

Medicine, Philadelphia, Lippincott Williams & Wilkins, 2020, 0025-7974

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.889

Kód RIV

RIV/00216224:14110/20:00116134

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1097/MD.0000000000020523

UT WoS

000549892300041

EID Scopus

2-s2.0-85086051166

Klíčová slova anglicky

anti-Mullerian hormone; fertility; muscular dystrophy; myotonic dystrophy; ovarian reserve

Štítky

14110221, 14110320, 14110411, 14119612, GPK, GPKgyn, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 3. 2021 15:44, Mgr. Tereza Miškechová

Anotace

V originále

Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Mullerian hormone) is currently considered the best measure of ovarian reserve. A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level. The MD1 group shows a significant decrease of AMH values (median 0.7ng/mL; range 0 - 4.9ng/mL) compared with age-matched healthy controls (P<.01). AMH levels were similar between patients and controls in terms of females with MD2 (P=.98), FSHD (P=.55) and cDMD (P=.60). This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.

Návaznosti

MUNI/A/1072/2017, interní kód MU

Název: Diagnostika a patofyziologie neuropatické bolesti (Akronym: PNB)

Investor: Masarykova univerzita, Diagnostika a patofyziologie neuropatické bolesti, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

MUNI/A/1325/2019, interní kód MU

Název: Diagnostika a patofyziologie neuropatické bolesti (Akronym: PNB)

Investor: Masarykova univerzita, Diagnostika a patofyziologie neuropatické bolesti, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

PARMOVÁ, Olesja; Eva VLČKOVÁ; Monika HULOVÁ; Livie MENSOVA; Igor CRHA; Petra STRÁDALOVÁ; Eva KRALICKOVA; Lenka JUŘÍKOVÁ; Martina PODBORSKÁ; Radim MAZANEC; Ladislav DUŠEK; Jiří JARKOVSKÝ; Josef BEDNAŘÍK; Stanislav VOHÁŇKA a Iva ŠROTOVÁ. Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies. Medicine. Philadelphia: Lippincott Williams & Wilkins, 2020, roč. 99, č. 23, s. 1-6. ISSN 0025-7974. Dostupné z: https://doi.org/10.1097/MD.0000000000020523.

@article{1673177,
   author = {Parmová, Olesja and Vlčková, Eva and Hulová, Monika and Mensova, Livie and Crha, Igor and Strádalová, Petra and Kralickova, Eva and Juříková, Lenka and Podborská, Martina and Mazanec, Radim and Dušek, Ladislav and Jarkovský, Jiří and Bednařík, Josef and Voháňka, Stanislav and Šrotová, Iva},
   article_location = {Philadelphia},
   article_number = {23},
   doi = {https://doi.org/10.1097/MD.0000000000020523},
   keywords = {anti-Mullerian hormone; fertility; muscular dystrophy; myotonic dystrophy; ovarian reserve},
   language = {eng},
   issn = {0025-7974},
   journal = {Medicine},
   title = {Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies},
   url = {https://journals.lww.com/md-journal/FullText/2020/06050/Anti_M_llerian_hormone_as_an_ovarian_reserve.42.aspx},
   volume = {99},
   year = {2020}
}

TY  - JOUR
ID  - 1673177
AU  - Parmová, Olesja - Vlčková, Eva - Hulová, Monika - Mensova, Livie - Crha, Igor - Strádalová, Petra - Kralickova, Eva - Juříková, Lenka - Podborská, Martina - Mazanec, Radim - Dušek, Ladislav - Jarkovský, Jiří - Bednařík, Josef - Voháňka, Stanislav - Šrotová, Iva
PY  - 2020
TI  - Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies
JF  - Medicine
VL  - 99
IS  - 23
SP  - 1-6
EP  - 1-6
PB  - Lippincott Williams & Wilkins
SN  - 00257974
KW  - anti-Mullerian hormone
KW  - fertility
KW  - muscular dystrophy
KW  - myotonic dystrophy
KW  - ovarian reserve
UR  - https://journals.lww.com/md-journal/FullText/2020/06050/Anti_M_llerian_hormone_as_an_ovarian_reserve.42.aspx
L2  - https://journals.lww.com/md-journal/FullText/2020/06050/Anti_M_llerian_hormone_as_an_ovarian_reserve.42.aspx
N2  - Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Mullerian hormone) is currently considered the best measure of ovarian reserve. A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level. The MD1 group shows a significant decrease of AMH values (median 0.7ng/mL; range 0 - 4.9ng/mL) compared with age-matched healthy controls (P<.01). AMH levels were similar between patients and controls in terms of females with MD2 (P=.98), FSHD (P=.55) and cDMD (P=.60). This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.
ER  -

PARMOVÁ, Olesja; Eva VLČKOVÁ; Monika HULOVÁ; Livie MENSOVA; Igor CRHA; Petra STRÁDALOVÁ; Eva KRALICKOVA; Lenka JUŘÍKOVÁ; Martina PODBORSKÁ; Radim MAZANEC; Ladislav DUŠEK; Jiří JARKOVSKÝ; Josef BEDNAŘÍK; Stanislav VOHÁŇKA a Iva ŠROTOVÁ. Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies. \textit{Medicine}. Philadelphia: Lippincott Williams \&{} Wilkins, 2020, roč.~99, č.~23, s.~1-6. ISSN~0025-7974. Dostupné z: https://doi.org/10.1097/MD.0000000000020523.

Přehled o publikaci